Targeting Transcription Factors of Tumor Angiogenesis and Lymphangiogenesis

Dear Colleagues,

Formation of the vascular system occurs through the coordination of multiple cell types and signaling networks. Exacerbated angiogenesis confers advantages to tumor growth and metastasis. Therefore, the molecular mechanisms of angiogenesis are major issues in the understanding of cancer progression and constitute an important therapeutic target in human cancer. In recent years, several transcription factors have been identified as angiogenic process drivers including HIF-1, NF-kB, AP-1, SOX family, PROX1, SP-1 and other endothelial and/or tumour transcription factors. Many transcription factors govern the expression of metabolic proteins, adhesion molecules, matrix components, and growth factors. Changes in the intracellular environment triggers HIF-1α stabilization, resulting in the secretion of pro-angiogenic growth factors.  Suppression of pro-angiogenic growth factors can be effective practical approaches for tumor treatment Angiogenesis inhibitors, like everolimus, bevacizumab, sunitinib, are drugs that impede the formation of new blood vessels, hence inhibit tumor growth.

This special issue welcomes research into the development of drugs using transcription factors as therapeutic targets and the development of new therapeutic approaches based on the identification of transcriptional pathways that regulate angiogenesis. Original research papers and review articles on these different areas are welcome.

Prof. Dr. Anca Maria Cimpean
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tumour angiogenesis
• lymphangiogenesis
• transcription factors
• personalized medicine
• targeted therapy